why choose us

First received: January 10, 2023

Clinical Trial: Elimination of Minimal Residual Disease After Transplant

Study Status: Completed

Recruit Status: RECRUITING

Condition: Multiple Myeloma

Study Type: INTERVENTIONAL


Official Title: Combination Post-transplant Consolidation Therapy With Isatuximab, Lenalidomide, Dexamethasone (IsaRD) in Multiple Myeloma Patients With Persistent Marrow Minimal Residual Disease (Elimination of MRD

Brief Summary: This is a single-center, single-arm, phase II study that will enroll multiple myeloma (MM) patients with persistent bone marrow minimal residual disease (MRD) post autologous stem cell transplant (ASCT) irrespective of the International Myeloma Working Group (IMWG) response.

Read more